Surgical robot maker Monogram to be acquired by biotech Zimmer; stock soars 78%

Shares of Monogram Technologies, a smaller company developing surgical robots to enable placement of patient optimized orthopedic implants, jumped 78% yesterday, July 14, hitting their highest mark since May 2023. The company announced it would be acquired at a premium by medical device maker Zimmer Biomet. With the deal, Zimmer Biomet expects to become the first and only company in orthopedics to offer a fully autonomous surgical robot.

Monogram soared more than 78% yesterday to $5.87 per share. The last time it closed that high was May 24, 2023, when the stock finished the day at $7.59 per share. In premarket trading today, the stock has given back 3.8% as of this writing. 

Investors reacted to the news that Monogram will be bought by Zimmer Biomet, which describes itself as a "global medical technology leader offering innovative implants and digital technologies." 

The deal values Monogram at $177 million, or $4.04 per share. This is almost 23% higher than the close on Friday, July 11, the last trading day before the deal was announced, when it closed at $3.29 per share.

Another $12.37 per share could be paid out if Monogram manages to achieve "certain product development, regulatory and revenue milestones... through 2030." 

The boards of both companies have already approved the deal, the press released stated. It still needs approval from Monogram shareholders and regulators.

Monogram develops robotic technology for total knee replacement procedures. In March, the company received regulatory clearance in the U.S., paving the way for commercial sales. Following the announcement on March 17, Monogram’s stock surged nearly 58%.

"With FDA clearance of the mBôs TKA System and the beginning of clinical trials in India, we believe there has been a major de-risking of the story and the company is poised for strong growth in 2026," Zacks Small-Cap Research argued in May. It forecast flat revenue growth in 2025, followed by 25-35% annually for the next decade. 

Monogram’s surgical robot is currently semi-autonomous, but the company is already developing a fully autonomous model. Zimmer Biomet plans to commercialize the technology alongside its implants starting in early 2027. Once the deal closes, it expects to become the first and only company in orthopedics to offer a fully autonomous surgical robot, the press release stated.

The acquisition gives Zimmer Biomet a first-mover advantage in the race for orthopedic robotics innovation, wrote Noble Capital Markets. "This acquisition isn’t just a strategic bolt-on; it’s a forward-looking bet on where surgery is headed – autonomous, data-driven, and personalized," the investment bank argues. "For investors seeking exposure to the convergence of AI, robotics, and healthcare, Zimmer Biomet’s expanding portfolio offers a compelling case for long-term value creation."

Monogram has added nearly 148% year to date, yet it is still down a little over 42% since its IPO in May 2023. The stock has one rating from Wall Street, a "buy," according to MarketWatch. The target price of $5.70 per share is below current quotes.

The AI translation of this story was reviewed by a human editor.